Contra-indicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.
- TRADE NAME: Toviaz (Pfizer)
- INDICATIONS: Overactive bladder syndrome; urinary incontinence, urgency and frequency
- CLASS: Muscarinic antagonist
- HALF-LIFE: 7 hours; 4 hours (oral)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Amantadine, Anticholinergics, Antidepressants, Antimuscarinics, Atazanavir, Botulinum Toxin (A & B), Carbamazepine, Cinacalcet, Clarithromycin, Conivaptan, CYP2D6 inhibitors, CYP3A4 inhibitors, CYP3AF inhibitors, Darunavir, Dasatinib, Deferasirox, Delavirdine, Duloxetine, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, PEG-Interferon, Phenobarbital, Phenytoin, Pramlintide, Rifampin, Ritonavir, Saquinavir, Secretin, St John's Wort, Telithromycin, Terbinafine, Tipranavir, Tocilizumab, Voriconazole
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fesoterodine in the Informa Healthcare journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
